Provided by Tiger Trade Technology Pte. Ltd.

NANOBIOTIX SPON ADS EACH REP 1 ORD SHS

41.51
+1.854.66%
Post-market: 41.510.00000.00%16:10 EDT
Volume:177.92K
Turnover:7.37M
Market Cap:2.11B
PE:-70.71
High:42.42
Open:40.13
Low:40.13
Close:39.66
52wk High:57.14
52wk Low:8.03
Shares:50.71M
Float Shares:33.57M
Volume Ratio:1.27
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5871
EPS(LYR):-0.5871
ROE:--
ROA:-10.06%
PB:-21.34
PE(LYR):-70.71

Loading ...

Nanobiotix Sa : Leerink Partners Raises Target Price to $46 From $37

THOMSON REUTERS
·
Jun 04

Press Release: Nanobiotix Provides First Quarter 2026 Operational and Financial Update

Dow Jones
·
Jun 03

Nanobiotix Joins the Euronext Tech Leaders Index

GlobeNewswire
·
Jun 02

Nanobiotix Closes $100 Million Global Offering

MT Newswires Live
·
May 27

NANOBIOTIX Announces Closing of Global Offering

GlobeNewswire
·
May 27

NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

GlobeNewswire
·
May 23

Nanobiotix falls -9.0%

TIPRANKS
·
May 22

Nanobiotix Prices $98.6 Million Global Follow-on Offering; Shares Fall

MT Newswires Live
·
May 21

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Uncertainty Surrounding US-Iran Talks

MT Newswires Live
·
May 21

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

GlobeNewswire
·
May 21

Nanobiotix announces EUR 75M global follow-on offering

TIPRANKS
·
May 21

Nanobiotix Announces Launch of Global Follow-On Offering

GlobeNewswire
·
May 21

Nanobiotix files EUR75M ordinary shares offering

TIPRANKS
·
May 21

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

GlobeNewswire
·
May 17

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

TIPRANKS
·
May 05

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

GlobeNewswire
·
May 05

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

GlobeNewswire
·
Apr 20

Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright

TIPRANKS
·
Apr 13

Nanobiotix Sa : Guggenheim Raises Target Price to $36 From $26

THOMSON REUTERS
·
Apr 02

Nanobiotix price target raised to $37 from $26 at Leerink

TIPRANKS
·
Apr 01